S-DUAL™
S-DUAL™ Bispecific Antibody Platform
S-DUAL™
The S-DUAL™ bispecific antibody platform delivers precise heavy chain and light chain pairing and produces IgG-like bispecific antibodies with >95% purity. Its dual-specificity therapeutic development capabilities allow faster commercialization while reducing risks of low immunogenicity antibodies.
This proprietary platform establishes an optimal path for successful biologics development. Discover related services in ADC (Antibody-Drug Conjugates) and Analytical Development.
Bispecific Antibody Platform Structure
-
- Low Immunogenicity Risk
-
- Similar structure to typical bispecific antibodies
- Antibody-derived protein only
-
- Correctly Paired bsAb
-
- Knob-into-Hole CH3 dimer applied on an additional domain in one Fab arm
- >95% purity
-
- Streamlined Access
-
- Favorable contract terms with competitive pricing
- Only parental antibody sequences needed to develop BsAb
A
B
Additional CH3 Domain
Knob-into-Hole
DEVELOPICK™
DEVELOPICK™ Rapid Developability Assessment
DEVELOPICK™
DEVELOPICK™ is a drug candidate screening platform that evaluates biologics in just one month with minimal material (80 mg). Through systematic biologics developability assessment, it scores drug candidates on stability, solubility, and formulation potential.
Key features include:
· Primary structure assessment
· Relative solubility testing
· Stress treatments (heat, pH)
· Hydrophobic interaction analysis
· Comprehensive data reporting
This platform empowers early, cost-efficient decision-making and integrates seamlessly with Analytical Development and Non-GMP / CGMP Manufacturing.
Developability Assessment Workflow
DEVELOPICK™ predicts candidates with the best potential for advancement by suggesting optimal formulation and scoring drug candidates based on stability screening.
- Material Supply
- Primary Structure Assessment
- Relative Solubility
- Basic Characterization
- Heat Stress Treatment
- Low & High pH Treatment
- Hydrophobic Interaction Analysis
- Data Reporting
- Material Supply
- Primary Structure Assessment
- Relative Solubility
- Basic Characterization
- Heat Stress Treatment
- Low & High pH Treatment
- Hydrophobic Interaction Analysis
- Data Reporting
S-CHOsient™
S-CHOsient™ ransient Expression System
S-CHOsient™
The S-CHOsient™ transient expression system enables early molecule generation and supports CHO cell transient expression workflows.
It allows researchers to:
· Produce material for internal studies
· Test vector ratios for transfection
· Generate reference material for process development
With robust productivity and quality, S-CHOsient™ strengthens early-stage programs and accelerates therapeutic antibody discovery services. Learn more about Biopharma Development and Drug Product Manufacturing.
Process Flow of S-CHOsient™
- Gene Synthesis / Vector Construction
- Transfection / Main Culture and Harvest
- Purification / Analytics
- Gene Synthesis / Vector Construction
- Transfection / Main Culture and Harvest
- Purification / Analytics
This streamlined process supports scalability and integration with Quality and Drug Substance Manufacturing.
Related Content
Accelerated Discovery with Advanced Platforms
Samsung Biologics provides advanced Late Discovery services that accelerate the transition from research to development. With our proprietary platforms, we help overcome scale-up challenges and enable faster, more efficient therapeutic antibody discovery services.
Our proprietary discovery technologies support bispecific antibody development and preclinical biologics development through three advanced platforms:
· S-DUAL™ bispecific antibody platform
· DEVELOPICK™ rapid developability assessment
· S-CHOsient™ transient expression system
By streamlining workflows, Samsung Biologics ensures that scale-up challenges are addressed early, helping clients bring innovations to market with speed and efficiency. Learn more about Process Development, Cell Line Development, and Biopharma Manufacturing.